CN117204573A - Composite prebiotic concentrate with effect of improving intestinal health and preparation method and application thereof - Google Patents
Composite prebiotic concentrate with effect of improving intestinal health and preparation method and application thereof Download PDFInfo
- Publication number
- CN117204573A CN117204573A CN202311297056.3A CN202311297056A CN117204573A CN 117204573 A CN117204573 A CN 117204573A CN 202311297056 A CN202311297056 A CN 202311297056A CN 117204573 A CN117204573 A CN 117204573A
- Authority
- CN
- China
- Prior art keywords
- parts
- oligosaccharide
- concentrate
- prebiotic
- intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 67
- 239000012141 concentrate Substances 0.000 title claims abstract description 40
- 230000007413 intestinal health Effects 0.000 title claims abstract description 37
- 239000002131 composite material Substances 0.000 title claims abstract description 30
- 230000000694 effects Effects 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229920000294 Resistant starch Polymers 0.000 claims abstract description 39
- 235000021254 resistant starch Nutrition 0.000 claims abstract description 39
- 239000000419 plant extract Substances 0.000 claims abstract description 37
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 28
- 239000000832 lactitol Substances 0.000 claims abstract description 27
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims abstract description 27
- 235000010448 lactitol Nutrition 0.000 claims abstract description 27
- 229960003451 lactitol Drugs 0.000 claims abstract description 27
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 25
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 23
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 23
- 229920001202 Inulin Polymers 0.000 claims abstract description 22
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 22
- 229940029339 inulin Drugs 0.000 claims abstract description 22
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 21
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- 229920002472 Starch Polymers 0.000 claims description 25
- 235000019698 starch Nutrition 0.000 claims description 25
- 239000008107 starch Substances 0.000 claims description 25
- 244000045195 Cicer arietinum Species 0.000 claims description 21
- 235000010523 Cicer arietinum Nutrition 0.000 claims description 21
- 239000012153 distilled water Substances 0.000 claims description 20
- 239000000706 filtrate Substances 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 16
- 235000004298 Tamarindus indica Nutrition 0.000 claims description 14
- 102000010445 Lactoferrin Human genes 0.000 claims description 13
- 108010063045 Lactoferrin Proteins 0.000 claims description 13
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 13
- 235000021242 lactoferrin Nutrition 0.000 claims description 13
- 229940078795 lactoferrin Drugs 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 13
- 238000004140 cleaning Methods 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 12
- 239000002244 precipitate Substances 0.000 claims description 12
- 238000007873 sieving Methods 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 230000005251 gamma ray Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 238000009210 therapy by ultrasound Methods 0.000 claims description 6
- 244000241838 Lycium barbarum Species 0.000 claims description 5
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 5
- 235000015468 Lycium chinense Nutrition 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 235000020510 functional beverage Nutrition 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 230000001678 irradiating effect Effects 0.000 claims description 2
- 238000005360 mashing Methods 0.000 claims description 2
- 240000004507 Abelmoschus esculentus Species 0.000 claims 2
- 240000004584 Tamarindus indica Species 0.000 claims 2
- 239000006286 aqueous extract Substances 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 28
- 241000186000 Bifidobacterium Species 0.000 abstract description 21
- 241000894006 Bacteria Species 0.000 abstract description 20
- 230000009286 beneficial effect Effects 0.000 abstract description 16
- 239000006041 probiotic Substances 0.000 abstract description 11
- 235000018291 probiotics Nutrition 0.000 abstract description 11
- 241000186660 Lactobacillus Species 0.000 abstract description 8
- 229940039696 lactobacillus Drugs 0.000 abstract description 7
- 241000606125 Bacteroides Species 0.000 abstract description 5
- 230000008855 peristalsis Effects 0.000 abstract description 4
- 241000194033 Enterococcus Species 0.000 abstract description 3
- 230000008944 intestinal immunity Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 238000013329 compounding Methods 0.000 abstract description 2
- 230000003993 interaction Effects 0.000 abstract description 2
- 229920001282 polysaccharide Polymers 0.000 description 22
- 239000005017 polysaccharide Substances 0.000 description 22
- 150000004676 glycans Chemical class 0.000 description 20
- 239000000243 solution Substances 0.000 description 14
- 241000596504 Tamarindus Species 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 241001075517 Abelmoschus Species 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 150000004666 short chain fatty acids Chemical class 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 238000003809 water extraction Methods 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 235000017784 Mespilus germanica Nutrition 0.000 description 5
- 244000182216 Mimusops elengi Species 0.000 description 5
- 235000000560 Mimusops elengi Nutrition 0.000 description 5
- 235000007837 Vangueria infausta Nutrition 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 150000002482 oligosaccharides Chemical class 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- ODEHMIGXGLNAKK-OESPXIITSA-N 6-kestotriose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 ODEHMIGXGLNAKK-OESPXIITSA-N 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000003871 intestinal function Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- -1 mannooligosaccharide Chemical compound 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001141 propulsive effect Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 241000160321 Parabacteroides Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000020553 functional juice drink Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960002983 loperamide hydrochloride Drugs 0.000 description 1
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- JBKPUQTUERUYQE-UHFFFAOYSA-O pralidoxime Chemical compound C[N+]1=CC=CC=C1\C=N\O JBKPUQTUERUYQE-UHFFFAOYSA-O 0.000 description 1
- 229960003370 pralidoxime Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007651 self-proliferation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composite prebiotic concentrate with an effect of improving intestinal health, and a preparation method and application thereof, wherein the composite prebiotic concentrate comprises the following components in parts by weight: 100 parts of water, 10-15 parts of inulin, 5-15 parts of fructo-oligosaccharide, 5-10 parts of galacto-oligosaccharide, 0.5-1.5 parts of xylo-oligosaccharide, 5-10 parts of lactitol, 2-5 parts of plant extract and 1-3 parts of resistant starch. The composite prebiotic concentrate can promote intestinal peristalsis by compounding various prebiotics, and simultaneously adds plant extracts and resistant starch, so that the bioavailability and stability of the prebiotics are improved, the adhesion and fixation of probiotics in intestinal tracts are facilitated, the intestinal microecological environment is improved, the abundance of beneficial bacteria such as bifidobacteria and lactobacillus in the intestinal tracts can be obviously improved through interaction among the raw materials, the abundance of bacteroides and enterococcus is reduced, and the intestinal immunity is further enhanced, so that the intestinal health is improved in all aspects.
Description
Technical Field
The invention belongs to the technical field of prebiotics, and particularly relates to a composite prebiotic concentrate with an effect of improving intestinal health, and a preparation method and application thereof.
Background
The intestinal tract is the largest digestive organ of human body, is an important place for digesting substances, absorbing nutrition and discharging metabolic waste, and is very important for maintaining normal metabolic function of human body. More than 500 bacteria inhabit in the intestinal tract of human body, and the number exceeds 10 15 Constitutes a huge micro-ecological system, and maintains the homeostasis of the internal environment through immune and metabolic pathways. Good intestinal status is important for the health function of the human body and for daily activities. In recent years, abdominal distension, abdominal pain, diarrhea and various enteritis diseases caused by unbalanced intestinal flora due to irregular work and rest time and poor eating habits are becoming more common, so that improving intestinal conditions and promoting body health by adjusting intestinal flora has become a research hotspot in the field of life science.
At present, two methods for regulating intestinal microecological environment exist, namely, probiotic bacteria supplementing. Normal intestinal flora, especially bifidobacteria, lactobacillus and the like, plays an important role in maintaining a good intestinal flora structure and body health, but live bacteria supplementing bacteria have a plurality of defects in the aspects of field planting force, live bacteria survival rate, transportation, preservation and the like; and secondly, the self proliferation of probiotics in the intestinal tract, namely the prebiotics and the supplementation of the probiotics. The physiological functions of the prebiotics are mainly realized by promoting the reproduction of beneficial bacteria in the intestines and regulating the microecological balance in the intestines, and are expressed in aspects of improving the intestinal functions, enhancing the immunity of organisms and the like.
Prebiotics are proposed on the basis of the concept of probiotics, and were first defined as "a non-digestible food ingredient that beneficially affects the host by selectively stimulating one or a limited number of bacteria already present in the colon, altering its growth and activity. With the innovation and upgrading of microorganism research tools (such as high-throughput sequencing), people have more comprehensive knowledge of the composition of microbial communities and more extensive and intensive research of prebiotics. The prebiotics can directly or indirectly act in the intestinal tract, and the application fields comprise food, cosmetics, livestock breeding and the like. The international prebiotic and prebiotic science association (ISAPP) of 2016 redefined prebiotics: substances that can be selectively utilized and transformed by the intestinal flora of the host under conditions conducive to the health of the host. Prebiotics in the new definition include non-carbohydrates, the site of action is not limited to the gastrointestinal tract, nor is its type limited to foods.
Although prebiotic products are commercially available, many products are formulated based on the physiological actions and effects of individual components, such as inulin, galactooligosaccharide, xylitol, mannooligosaccharide, dextran, etc., but single products have a significant limitation. Because of the unique individuality of the various oligosaccharides in the various oligosaccharide prebiotics, for example, the various oligosaccharides have different promotion effects and strengths on various probiotics; the inhibition ability to various harmful bacteria is different; in the same colon ecological environment, the fermentation time is different; the amount of gas produced during fermentation is different; the types and the amounts of the short chain fatty acids generated during fermentation and decomposition are different; the adhesion capacity in the large intestine wall is different; the fermentation activities of the various regions in the large intestine are different, and the like, so that the limitation of single prebiotic products is large.
Therefore, aiming at different types of prebiotics and different utilization degrees of the prebiotics by intestinal flora, a composite prebiotic product which has the flora optimizing function and is beneficial to adhesion and colonization of the probiotics in the intestinal tract is developed, so that the composite prebiotic product for promoting the health of the intestinal tract has great significance.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide the compound prebiotic concentrate with the effect of improving the intestinal health, and the preparation method and the application thereof.
In order to achieve the above purpose, the present invention provides the following technical solutions:
the composite prebiotic concentrate with the effect of improving intestinal health comprises the following components in parts by weight:
100 parts of water, 10-15 parts of inulin, 5-15 parts of fructo-oligosaccharide, 5-10 parts of galacto-oligosaccharide, 0.5-1.5 parts of xylo-oligosaccharide, 5-10 parts of lactitol, 2-5 parts of plant extract and 1-3 parts of resistant starch.
Inulin, as a natural soluble dietary fiber, is hardly hydrolyzed and digested by gastric acid, but is fermented by a large amount of beneficial microorganisms in the colon, thus having various health functions such as regulating blood glucose, not causing blood glucose fluctuations, not affecting blood glucose level and insulin content in blood, improving intestinal function, promoting mineral absorption, etc.
The fructo-oligosaccharide is a non-reducing sugar, is a functional oligosaccharide such as kestose, kestose and kestose which are formed by combining 1-3 fructosyl groups with the fructosyl groups in sucrose through beta (2-1) glycosidic bonds, has a polymerization degree of 2-9, is a natural active ingredient, and is also an excellent water-soluble dietary fiber. Fructo-oligosaccharides are well-known bifidus factors, and can be subjected to glycolysis by beneficial bacteria such as bifidobacteria, and are partially converted into short-chain fatty acids (mainly acetic acid, propionic acid and butyric acid) and a small amount of gas, so that the fructo-oligosaccharides are beneficial to the health of a host.
The galactooligosaccharide is a novel functional substance, is a functional oligosaccharide with natural properties, has good palatability, water solubility and stability, can proliferate probiotics, especially bifidobacteria in human intestinal tracts after entering human bodies, and can inhibit the growth of putrefying bacteria. Has outstanding advantages in improving the quantity of bifidobacteria, reducing the quantity of clostridium, producing lactic acid and producing less gas, and has physiological functions of adjusting the balance of intestinal flora, having low caloric value, promoting mineral absorption, promoting the discharge of toxic metabolites and the like for human bodies. In addition, probiotics in the intestinal tract can generate a large amount of extracellular polysaccharide while utilizing galacto-oligosaccharide for proliferation, and the extracellular polysaccharide not only has anti-tumor activity and immune activity, but also can promote the long-term colonization of the probiotics in the intestinal tract.
Xylo-oligosaccharide is a functional polymeric sugar, which is formed by combining 2-7 xylose molecules with beta-1, 4 glycosidic bonds, and is also called as xylo-oligosaccharide. The xylo-oligosaccharide is hardly decomposed by enzyme system in human digestive tract, and has low heat quantity, but can directly enter large intestine, and can be utilized by microorganism in intestinal tract to promote proliferation of probiotics such as bifidobacterium and lactobacillus. In addition, the fermentation products of the xylo-oligosaccharide such as lactic acid, acetic acid, propionic acid, butyric acid and the like can acidify the intestinal environment, on one hand, can promote the intestinal function, influence the absorption of internal lipid and mineral substances and prevent colon cancer; on the other hand, the low pH intestinal environment can inhibit the growth of clostridium, bacteroides and other conditional pathogenic bacteria, reduce the formation of toxic metabolites (such as amine), reduce the burden on liver and protect liver. Meanwhile, the xylo-oligosaccharide also has the physiological functions of preventing constipation, reducing serum cholesterol, improving the immunity of organisms and the like.
Lactitol, also known as lactitol, is a sweetener, the chemical nature of which is 4-O-beta-D-galactopyranose-D-sorbitol, and is a disaccharide alcohol obtained by reduction of lactose. Numerous studies have shown that lactitol is capable of significantly promoting the growth of intestinal beneficial bacteria, but is not utilized by harmful bacteria and can be categorized as a prebiotic. Meanwhile, lactitol is not absorbed by the small intestine basically, so that the lactitol reaches the large intestine and is fermented by microorganisms in the intestinal tract to generate short-chain fatty acids (lactic acid, acetic acid, propionic acid, butyric acid and the like), the acidity of the intestinal tract is reduced, and the intestinal tract peristalsis is stimulated; the transport rate of the colon is positively correlated with the dosage of lactitol, since lactitol increases intraluminal water retention and intestinal peristalsis, thereby causing an increase in the volume of excretions, increasing the rate of excretion, and promoting defecation.
Preferably, the compound prebiotic concentrate with the effect of improving intestinal health comprises the following components in parts by weight: 100 parts of water, 10-13 parts of inulin, 8-15 parts of fructo-oligosaccharide, 7-10 parts of galacto-oligosaccharide, 0.7-1.3 parts of xylo-oligosaccharide, 5-8 parts of lactitol, 2-4 parts of plant extract and 2-3 parts of resistant starch.
Preferably, the compound prebiotic concentrate with the effect of improving intestinal health comprises the following components in parts by weight: 100 parts of water, 12-13 parts of inulin, 10-13 parts of fructo-oligosaccharide, 7-9 parts of galacto-oligosaccharide, 0.9-1.1 parts of xylo-oligosaccharide, 6-7 parts of lactitol, 3-4 parts of plant extract and 2-3 parts of resistant starch.
Preferably, the preparation method of the plant extract comprises the following steps: respectively mashing tamarind kernel, fructus Lycii and okra, adding into distilled water, soaking at 20-30deg.C for 1-2 hr, adding citric acid, extracting with water, filtering to obtain filtrate, adding lactoferrin into the filtrate, stirring, ultrasonic treating, irradiating, concentrating under reduced pressure, and drying to obtain the plant extract.
The tamarind seed contains rich polysaccharide components, the polysaccharide content is up to 50%, the tamarind seed is one of main components in the seed, and the tamarind seed has the characteristics of good thickening property, acid and alkali resistance, heat resistance, biocompatibility, intestinal flora regulation and the like, has the functions of preventing constipation, improving intestinal flora and playing intestinal immunity.
The wolfberry polysaccharide is a compound polysaccharide which is mainly composed of acid heteropolysaccharide and polypeptide or protein and composed of rhamnose, arabinose, xylose, mannose, galactose, glucose and galacturonic acid, and also contains neutral heteropolysaccharide and compound polysaccharide composed of glucan and polypeptide or protein, and the wolfberry polysaccharide can change microbial communities after 24 hours of fermentation, so that the production of short chain fatty acid is obviously promoted, and the relative abundance of bacteroides, bifidobacteria, lactobacillus, clostridium, pralidoxime and Ke Linzao is improved.
The mucopolysaccharide rich in okra forms a stable polysaccharide protective film on the gastrointestinal wall to prevent gastric acid corrosion, so that the effects of protecting gastrointestinal mucosa and repairing ulcers are achieved, the abundant polysaccharide can obviously improve the abundance of bifidobacteria and lactobacillus in the intestinal tract, reduce the abundance of bacteroides and enterococcus and is beneficial to the field planting and proliferation of beneficial bacteria groups, and the intestinal health is improved.
Preferably, the mass ratio of tamarind kernel to wolfberry fruit to okra to distilled water to citric acid is 40-60:30-40:10-20:1200-1800:0.4-0.8, and the mass ratio of filtrate to lactoferrin is 100:3-6.
Preferably, the temperature of the water extraction is 80-90 ℃ and the time is 2-3 hours; the power of the ultrasonic treatment is 300-400W, and the time is 20-30min; the irradiation treatment comprises the following steps: the dose is 5-8kGy through gamma ray irradiation.
Preferably, the preparation method of the resistant starch comprises the following steps:
adding 100 parts of fresh chickpeas into 500 parts of distilled water, crushing, sieving with a 100-mesh sieve, standing filtrate, precipitating for 10 hours, removing supernatant, cleaning lower-layer precipitate, standing for 8 hours, removing supernatant, cleaning the surface of the lower-layer precipitate, and then placing in a 50 ℃ oven to dry until the water content is less than 10 percent; adding 100 parts of chickpea starch into 500 parts of distilled water, stirring to obtain starch emulsion, then carrying out microwave treatment on the starch emulsion with the microwave treatment power of 600-700W for 100-150s, cooling after the treatment is finished, refrigerating for 12h at 4 ℃, drying at 50 ℃, crushing, sieving and purifying to obtain the resistant starch.
Chickpea is rich in carbohydrate, protein, vitamin and other nutrients, is a high-quality vegetable food source, and starch is the most main carbohydrate in chickpea, and the content of the starch is up to 40% -60%. The chickpea starch contains higher resistant starch, and the resistant starch has the effects of regulating the composition of intestinal flora, promoting the growth of beneficial intestinal bacteria, promoting the generation of short-chain fatty acid in intestinal tracts, preventing brain cancer and colonitis, and improving the health of intestinal tracts.
The invention also provides a preparation method of the composite prebiotic concentrate with the effect of improving intestinal health, which comprises the following steps of:
weighing water, inulin, fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide, lactitol, plant extract and resistant starch according to a formula, mixing, stirring uniformly, concentrating under reduced pressure to 1/2 of the original volume, packaging, and sterilizing.
The invention also protects the application of the composite prebiotic concentrate with the effect of improving intestinal health in the functional food or beverage with the effect of intestinal health.
Compared with the prior art, the invention has the following beneficial effects:
(1) According to the composite prebiotic concentrate with the effect of improving intestinal health, disclosed by the invention, by compounding a plurality of prebiotics, intestinal peristalsis can be promoted, and simultaneously, the plant extract and resistant starch are added, so that the bioavailability and stability of the prebiotics are improved, adhesion and field planting of the prebiotics in intestinal tracts are also facilitated, the intestinal microecological environment is improved, the abundance of beneficial bacteria such as bifidobacteria and lactobacillus in the intestinal tracts can be obviously improved through interaction among the raw materials, the abundance of bacteroides and enterococcus is reduced, and further, the intestinal immunity is enhanced, so that the intestinal health is improved in all aspects.
(2) According to the composite prebiotic concentrate with the effect of improving intestinal health, tamarind kernels, medlar and okra are taken as raw materials in the added plant extract, polysaccharide in the plant is extracted by a hot water extraction method, and citric acid is added in the extraction process, so that the extraction rate of plant polysaccharide can be improved, and on the other hand, the tamarind polysaccharide solution is too high in viscosity and is not suitable for direct use, and the molecular weight of the tamarind polysaccharide can be reduced, the branching degree is reduced, and the solution viscosity is reduced through extraction under an acidic condition; then lactoferrin is added, and then the polysaccharide molecular chain in the plant extract is degraded by ultrasonic and irradiation treatment, the molecular mass is reduced in a gradient way, the molecular mass distribution is widened, and ultrasonic vibration energy cuts off certain chemical bonds in the polysaccharide, so that the molecular weight of the polysaccharide is reduced and the water solubility is increased; the added lactoferrin can form a soluble compound with polysaccharide in the plant extract through a non-covalent bond, so that the plant extract has stronger stability and bioactivity, meanwhile, the polysaccharide in the plant extract also obviously enhances the stability of the lactoferrin under the thermal condition, reduces the change of the lactoferrin in the subsequent decompression concentration process of the prebiotic concentrated solution, and finally improves the bioactivity and the utilization rate of the prebiotic concentrated solution, and on the other hand, the lactoferrin can also effectively inhibit the growth of bacteria such as escherichia coli, salmonella typhi, streptococcus, legionella pneumophila and the like, reduce the infection of gastrointestinal bacteria, does not influence the growth of lactobacillus and bifidobacterium, and is beneficial to improving the intestinal microecological environment.
(3) The polysaccharide in the plant extract interacts with flora in the intestinal tract to increase the content of short-chain fatty acid, inhibit the growth of pathogenic bacteria escherichia and multiranus, and promote the proliferation of beneficial bacteria lactobacillus, parabacteroides, praecox and fecal bacillus together with inulin, fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide and lactitol; in addition, the matrimony vine polysaccharide and okra polysaccharide can improve the adhesion rate of beneficial bacteria in intestinal tracts, repel the adhesion and invasion of pathogenic bacteria to normal cells, and adjust the balance of intestinal flora; through adding chickpea resistant starch, the resistant starch can evade the digestion of small intestine, and after fermentation, the resistant starch can promote the discharge of harmful substances in the intestine, promote the health of the intestine, and bifidobacteria in the colon can utilize the resistant starch and adhere to resistant starch particles, so that the resistance of the chickpea resistant starch to low pH value is improved, the proliferation of bifidobacteria in the intestine is promoted, and the health of the intestine is further promoted.
Detailed Description
The technical solutions of the present invention will be clearly and completely described in connection with the embodiments, and it is obvious that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
A composite prebiotic concentrate with improved intestinal health comprising the following components: 1kg of water, 120g of inulin, 120g of fructo-oligosaccharide, 80g of galacto-oligosaccharide, 10g of xylo-oligosaccharide, 70g of lactitol, 35g of plant extract and 20g of resistant starch.
The preparation method of the plant extract comprises the following steps: respectively smashing 50g of tamarind kernels, 30g of medlar and 20g of okra, adding into 1500g of distilled water, soaking for 1.5h at 25 ℃, then adding 0.6g of citric acid, extracting with water at 85 ℃ for 2.5h, filtering after the water extraction is finished to obtain filtrate, then adding 5g of lactoferrin into 100g of filtrate, uniformly stirring, performing ultrasonic treatment with the power of 350W for 25min, and then performing irradiation treatment, wherein the irradiation treatment is as follows: and (3) performing gamma-ray irradiation with the dosage of 7kGy, concentrating under reduced pressure after the irradiation is finished, and drying to obtain the plant extract.
The preparation method of the resistant starch comprises the following steps:
adding 100g of fresh chickpea into 500g of distilled water, crushing, sieving with a 100-mesh sieve, standing filtrate, precipitating for 10h, removing supernatant, cleaning lower precipitate, standing for 8h, removing supernatant, cleaning the surface of lower precipitate, and drying in a 50 ℃ oven until the water content is less than 10%, wherein chickpea starch is obtained; adding 100g of chickpea starch into 500g of distilled water, stirring to obtain starch emulsion, then carrying out microwave treatment on the starch emulsion with the microwave treatment power of 650W for 130s, cooling after the treatment is finished, refrigerating at 4 ℃ for 12h, drying at 50 ℃, crushing, sieving and purifying to obtain the resistant starch.
A preparation method of a composite prebiotic concentrate with the effect of improving intestinal health comprises the following steps:
weighing water, inulin, fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide, lactitol, plant extract and resistant starch according to a formula, mixing, stirring uniformly, concentrating under reduced pressure to 1/2 of the original volume, packaging, and sterilizing.
Example 2
A composite prebiotic concentrate with improved intestinal health comprising the following components: 1kg of water, 100g of inulin, 150g of fructo-oligosaccharide, 100g of galacto-oligosaccharide, 5g of xylo-oligosaccharide, 50g of lactitol, 20g of plant extract and 30g of resistant starch.
The preparation method of the plant extract comprises the following steps: respectively smashing 40g of tamarind kernels, 40g of medlar and 20g of okra, adding into 1200 distilled water, soaking for 2 hours at 20 ℃, then adding 0.4g of citric acid, extracting with water at 80 ℃ for 3 hours, filtering after the water extraction is finished to obtain filtrate, then adding 3g of lactoferrin into 100g of filtrate, uniformly stirring, carrying out ultrasonic treatment with the power of 300W for 30 minutes, and then carrying out irradiation treatment, wherein the irradiation treatment is as follows: and (3) performing gamma-ray irradiation with the dosage of 5kGy, concentrating under reduced pressure after the irradiation is finished, and drying to obtain the plant extract.
The preparation method of the resistant starch comprises the following steps:
adding 100g of fresh chickpea into 500g of distilled water, crushing, sieving with a 100-mesh sieve, standing filtrate, precipitating for 10h, removing supernatant, cleaning lower precipitate, standing for 8h, removing supernatant, cleaning the surface of lower precipitate, and drying in a 50 ℃ oven until the water content is less than 10%, wherein chickpea starch is obtained; adding 100g of chickpea starch into 500g of distilled water, stirring to obtain starch emulsion, then carrying out microwave treatment on the starch emulsion with the microwave treatment power of 600W for 150s, cooling after the treatment is finished, refrigerating at 4 ℃ for 12h, drying at 50 ℃, crushing, sieving and purifying to obtain the resistant starch.
A preparation method of a composite prebiotic concentrate with the effect of improving intestinal health comprises the following steps:
weighing water, inulin, fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide, lactitol, plant extract and resistant starch according to a formula, mixing, stirring uniformly, concentrating under reduced pressure to 1/2 of the original volume, packaging, and sterilizing.
Example 3
A composite prebiotic concentrate with improved intestinal health comprising the following components: 1kg of water, 150g of inulin, 100g of fructo-oligosaccharide, 50g of galacto-oligosaccharide, 15g of xylo-oligosaccharide, 100g of lactitol, 50g of plant extract and 10g of resistant starch.
The preparation method of the plant extract comprises the following steps: respectively smashing 60g of tamarind kernels, 30g of medlar and 10g of okra, adding 1800g of distilled water, soaking for 1h at 30 ℃, then adding 0.8g of citric acid, extracting with water at 90 ℃ for 2h, filtering after the water extraction is finished to obtain filtrate, then adding 6g of lactoferrin into 100g of filtrate, uniformly stirring, carrying out ultrasonic treatment with the power of 400W for 20min, and then carrying out irradiation treatment, wherein the irradiation treatment is as follows: and (3) performing gamma-ray irradiation with the dosage of 8kGy, concentrating under reduced pressure after the irradiation is finished, and drying to obtain the plant extract.
The preparation method of the resistant starch comprises the following steps:
adding 100g of fresh chickpea into 500g of distilled water, crushing, sieving with a 100-mesh sieve, standing filtrate, precipitating for 10h, removing supernatant, cleaning lower precipitate, standing for 8h, removing supernatant, cleaning the surface of lower precipitate, and drying in a 50 ℃ oven until the water content is less than 10%, wherein chickpea starch is obtained; adding 100g of chickpea starch into 500g of distilled water, stirring to obtain starch emulsion, then carrying out microwave treatment on the starch emulsion with the microwave treatment power of 700W for 100s, cooling after the treatment is finished, refrigerating at 4 ℃ for 12h, drying at 50 ℃, crushing, sieving and purifying to obtain the resistant starch.
A preparation method of a composite prebiotic concentrate with the effect of improving intestinal health comprises the following steps:
weighing water, inulin, fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide, lactitol, plant extract and resistant starch according to a formula, mixing, stirring uniformly, concentrating under reduced pressure to 1/2 of the original volume, packaging, and sterilizing.
Comparative example 1
A composite prebiotic concentrate with improved intestinal health comprising the following components: 1kg of water, 120g of inulin, 120g of fructo-oligosaccharide, 80g of galacto-oligosaccharide, 10g of xylo-oligosaccharide, 70g of lactitol and 20g of resistant starch.
The preparation method of the resistant starch comprises the following steps:
adding 100g of fresh chickpea into 500g of distilled water, crushing, sieving with a 100-mesh sieve, standing filtrate, precipitating for 10h, removing supernatant, cleaning lower precipitate, standing for 8h, removing supernatant, cleaning the surface of lower precipitate, and drying in a 50 ℃ oven until the water content is less than 10%, wherein chickpea starch is obtained; adding 100g of chickpea starch into 500g of distilled water, stirring to obtain starch emulsion, then carrying out microwave treatment on the starch emulsion with the microwave treatment power of 650W for 130s, cooling after the treatment is finished, refrigerating at 4 ℃ for 12h, drying at 50 ℃, crushing, sieving and purifying to obtain the resistant starch.
A preparation method of a composite prebiotic concentrate with the effect of improving intestinal health comprises the following steps:
weighing water, inulin, fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide, lactitol and resistant starch according to a formula, mixing, stirring uniformly, concentrating under reduced pressure to 1/2 of the original volume, filling, and sterilizing.
Comparative example 2
A composite prebiotic concentrate with improved intestinal health comprising the following components: 1kg of water, 120g of inulin, 120g of fructo-oligosaccharide, 80g of galacto-oligosaccharide, 10g of xylo-oligosaccharide, 70g of lactitol and 35g of plant extract.
The preparation method of the plant extract comprises the following steps: respectively smashing 50g of tamarind kernels, 30g of medlar and 20g of okra, adding into 1500g of distilled water, soaking for 1.5h at 25 ℃, then adding 0.6g of citric acid, extracting with water at 85 ℃ for 2.5h, filtering after the water extraction is finished to obtain filtrate, then adding 5g of lactoferrin into 100g of filtrate, uniformly stirring, performing ultrasonic treatment with the power of 350W for 25min, and then performing irradiation treatment, wherein the irradiation treatment is as follows: and (3) performing gamma-ray irradiation with the dosage of 7kGy, concentrating under reduced pressure after the irradiation is finished, and drying to obtain the plant extract.
A preparation method of a composite prebiotic concentrate with the effect of improving intestinal health comprises the following steps:
weighing water, inulin, fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide, lactitol and plant extract according to the formula, mixing, stirring uniformly, concentrating under reduced pressure to 1/2 of the original volume, packaging, and sterilizing.
The compound prebiotic concentrates prepared in examples 1-3 and comparative examples 1-2 were added to fruit juice beverages at an addition level of 10wt% respectively to obtain fruit juice beverages with intestinal tract health function, and the effect on intestinal tract function was tested.
140 Kunming mice were selected, each half of the male and female mice were randomly allocated to 7 groups of 20 mice each, which were respectively a blank group, a model control group, an example 1 group, an example 2 group, an example 3 group, a comparative example 1 group, and a comparative example 2 group, and each group was filled with loperamide hydrochloride 10mg/kg·bw for 1 time/d except the blank group, and was continuously filled with stomach for 7d, and all mice were fed with water and free to drink food, thereby establishing a constipation model. The prepared functional juice drink for intestinal health care is respectively infused into the stomach of mice, and the blank group and the model control group are infused with equal volumes of physiological saline, 0.3mL of the normal saline is infused into the stomach each day, the stomach is continuously infused for 14 days, and all the mice drink water and eat. After 14 days, each group of mice is fasted without water for 12 hours; then, each group was subjected to the last gastric lavage, after 1h of gastric lavage administration, activated carbon was administered after 30min, mice were sacrificed after 15min of dislocation, the intestinal membranes were opened for separation, small intestines were cut off, the carbon powder advancing distance was measured, and the small intestine advancing rate (%) was calculated.
Advancement (%) = activated charcoal advancement length (cm)/total small intestine length (cm) ×100%
TABLE 1 results of small intestine propulsion experiments
As can be seen from the above Table 1, the model control group has significantly lower intestinal propulsive rate than that of the blank group, which indicates that the constipation model is successful, and meanwhile, the composite prebiotic concentrate (example 1-3 group) prepared by the invention has significantly higher intestinal propulsive rate than that of the comparative example 1 group, the comparative example 2 group and the model control group, which indicates that the composite prebiotic concentrate can effectively promote gastrointestinal motility and accelerate fecal discharge.
The composite prebiotic concentrates with improved intestinal health prepared in example 1 and comparative examples 1-2 were tested for bifidobacterium adhesion and the concentrates were formulated as 5wt% composite prebiotic solutions for use.
Culturing Bifidobacterium (Bifidobacterium adolescentis JCM 1275, collection number: CGMCC 1.2190) in MRS culture medium at 37deg.C for 22 hr to logarithmic phase, centrifuging the bacterial suspension in centrifuge, collecting bacterial cells, washing with PBS buffer solution with pH of 7.3 for 2 times, removing supernatant, adding MEM basic culture solution into bacterial mud, and diluting the bacterial suspension to 5.0X10 9 CFU/mL was ready for use. A sterile coverslip was placed in each well of a six-well petri dish and then 2mL of Caco-2 cell suspension (1X 10) 5 CFU/mL), and placed in a carbon dioxide incubator at 37 ℃ with a relative humidity of 98%. Culturing Caco-2 cells for about 48h until the cell density reaches 80%, discarding the culture solution, washing the Caco-2 cell layer with MEM basal culture solution to remove serum and antibody, repeating twice, and discarding the culture solution.
The bifidobacterium suspension prepared above (5.0X10) was added to a six-well dish 9 CFU/mL), 2mL per well, and 1mL of the 5wt% complex prebiotic solution prepared above was added per well, marked. Placing six-hole culture dish containing bacterial suspension and 5wt% composite prebiotic solution Caco-2 cells at 37deg.C for co-culturing for 4 hr, discarding culture solution, and using pH to obtain the final productThe cell layer was washed with PBS buffer 7.3 and repeated three times. Cells adhered to the Caco-2 cell layer were fixed with 4% paraformaldehyde for 20min. The coverslip in the six-well petri dish was removed, placed on a slide, and gram stained. Finally, the bifidobacterium cells adhered to the Caco-2 cells were counted under a microscope, the number of bifidobacteria adhered to each Caco-2 cell (CFU/cell) was calculated, and the average value was calculated as the cell adhesion rate of the bifidobacterium, and the test results were shown in Table 2 below.
TABLE 2
| Adhesion Rate/(CFU/cell) | |
| Example 1 | 16±3.4 |
| Comparative example 1 | 9±1.8 |
| Comparative example 2 | 11±2.3 |
As can be seen from table 2, the composite prebiotic concentrate with improved intestinal health prepared by the invention can promote the adhesion rate of bifidobacteria to Caco-2 cells, is beneficial to the colonization of bifidobacteria in the intestinal tract, and can compete with harmful bacteria for adhesion sites after the bifidobacteria are adhered, thereby improving the abundance of intestinal flora and generating nutrients to inhibit pathogens, and further improving the intestinal health.
Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made therein without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (10)
1. The composite prebiotic concentrate with the effect of improving intestinal health is characterized by comprising the following components in parts by weight:
100 parts of water, 10-15 parts of inulin, 5-15 parts of fructo-oligosaccharide, 5-10 parts of galacto-oligosaccharide, 0.5-1.5 parts of xylo-oligosaccharide, 5-10 parts of lactitol, 2-5 parts of plant extract and 1-3 parts of resistant starch.
2. The complex prebiotic concentrate with improved intestinal health of claim 1, comprising the following components in parts by weight: 100 parts of water, 10-13 parts of inulin, 8-15 parts of fructo-oligosaccharide, 7-10 parts of galacto-oligosaccharide, 0.7-1.3 parts of xylo-oligosaccharide, 5-8 parts of lactitol, 2-4 parts of plant extract and 2-3 parts of resistant starch.
3. The complex prebiotic concentrate with improved intestinal health of claim 1, comprising the following components in parts by weight: 100 parts of water, 12-13 parts of inulin, 10-13 parts of fructo-oligosaccharide, 7-9 parts of galacto-oligosaccharide, 0.9-1.1 parts of xylo-oligosaccharide, 6-7 parts of lactitol, 3-4 parts of plant extract and 2-3 parts of resistant starch.
4. The complex prebiotic concentrate with improved intestinal health of claim 1 wherein the plant extract is prepared by the process of: respectively mashing tamarind kernel, fructus Lycii and okra, adding into distilled water, soaking at 20-30deg.C for 1-2 hr, adding citric acid, extracting with water, filtering to obtain filtrate, adding lactoferrin into the filtrate, stirring, ultrasonic treating, irradiating, concentrating under reduced pressure, and drying to obtain the plant extract.
5. The compound prebiotic concentrate with improved intestinal health according to claim 4, wherein the mass ratio of tamarind seed kernel, wolfberry fruit, okra, distilled water and citric acid is 40-60:30-40:10-20:1200-1800:0.4-0.8, and the mass ratio of filtrate and lactoferrin is 100:3-6.
6. The complex prebiotic concentrate of claim 4 wherein the temperature of the aqueous extract is 80-90 ℃ for 2-3 hours; the power of the ultrasonic treatment is 300-400W, and the time is 20-30min; the irradiation treatment comprises the following steps: the dose is 5-8kGy through gamma ray irradiation.
7. A complex prebiotic concentrate with improved intestinal health as defined in claim 1 wherein the resistant starch is prepared by the process of:
adding 100 parts of fresh chickpeas into 500 parts of distilled water, crushing, sieving with a 100-mesh sieve, standing filtrate, precipitating for 10 hours, removing supernatant, cleaning lower-layer precipitate, standing for 8 hours, removing supernatant, cleaning the surface of the lower-layer precipitate, and then placing in a 50 ℃ oven to dry until the water content is less than 10 percent; adding 100 parts of chickpea starch into 500 parts of distilled water, stirring to obtain starch emulsion, then carrying out microwave treatment on the starch emulsion, cooling after the treatment is finished, refrigerating for 12 hours at 4 ℃, drying at 50 ℃, and obtaining the resistant starch after crushing, sieving and purifying.
8. The complex prebiotic concentrate of claim 7 wherein the microwave treatment has a power of 600W to 700W for a period of 100s to 150s.
9. A method of preparing a complex prebiotic concentrate of any of claims 1-8 having improved intestinal health comprising the steps of:
weighing water, inulin, fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide, lactitol, plant extract and resistant starch according to a formula, mixing, stirring uniformly, concentrating under reduced pressure to 1/2 of the original volume, packaging, and sterilizing.
10. Use of a complex prebiotic concentrate according to any of claims 1-8 in a functional food or beverage for the health care of the intestinal tract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311297056.3A CN117204573B (en) | 2023-10-09 | 2023-10-09 | Composite prebiotic concentrate with effect of improving intestinal health and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311297056.3A CN117204573B (en) | 2023-10-09 | 2023-10-09 | Composite prebiotic concentrate with effect of improving intestinal health and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117204573A true CN117204573A (en) | 2023-12-12 |
| CN117204573B CN117204573B (en) | 2024-03-15 |
Family
ID=89037159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311297056.3A Active CN117204573B (en) | 2023-10-09 | 2023-10-09 | Composite prebiotic concentrate with effect of improving intestinal health and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117204573B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840361A (en) * | 1997-04-09 | 1998-11-24 | Beech-Nut Nutrition Corporation | Fructan-containing baby food compositions and methods therefor |
| CN109718289A (en) * | 2019-01-07 | 2019-05-07 | 云浮市新金山生物科技股份有限公司 | A kind of galactooligosaccharide prebiotic compositions treating or preventing enterogastric diseases |
| CN111227261A (en) * | 2020-01-21 | 2020-06-05 | 广东量子高科微生态医疗有限公司 | Prebiotic composition and application thereof |
| CN114794189A (en) * | 2022-05-23 | 2022-07-29 | 江南大学 | Low-starch digestible chickpea biscuit and preparation method thereof |
| CN116784442A (en) * | 2023-07-17 | 2023-09-22 | 湖北时间种子生命科技有限公司 | Prebiotic western Mei Qianwei fruit drink with intestinal health improving function and preparation method thereof |
-
2023
- 2023-10-09 CN CN202311297056.3A patent/CN117204573B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840361A (en) * | 1997-04-09 | 1998-11-24 | Beech-Nut Nutrition Corporation | Fructan-containing baby food compositions and methods therefor |
| CN109718289A (en) * | 2019-01-07 | 2019-05-07 | 云浮市新金山生物科技股份有限公司 | A kind of galactooligosaccharide prebiotic compositions treating or preventing enterogastric diseases |
| CN111227261A (en) * | 2020-01-21 | 2020-06-05 | 广东量子高科微生态医疗有限公司 | Prebiotic composition and application thereof |
| CN114794189A (en) * | 2022-05-23 | 2022-07-29 | 江南大学 | Low-starch digestible chickpea biscuit and preparation method thereof |
| CN116784442A (en) * | 2023-07-17 | 2023-09-22 | 湖北时间种子生命科技有限公司 | Prebiotic western Mei Qianwei fruit drink with intestinal health improving function and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117204573B (en) | 2024-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1663573B (en) | A stable and safe microecological formulation, its preparation and usage | |
| CN106619743A (en) | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink | |
| CN1099289C (en) | Medicinal prepn. contg. beneficial bacteria named 'Junyikang' and method for preparing same | |
| CN105639631A (en) | Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide | |
| CN112056399A (en) | Probiotic composition for enhancing immunity and application thereof | |
| CN113142302B (en) | Probiotic yogurt with blood glucose reducing effect and preparation method thereof | |
| CN110959866A (en) | High-fiber chewable tablet containing probiotics and preparation method thereof | |
| CN115349639B (en) | Probiotic slow-release system for improving immunity and preparation method and application thereof | |
| CN114921363A (en) | Composite probiotics for inhibiting fat accumulation and application thereof | |
| KR20040027180A (en) | Lactic Acid Bacteria-Fermenting Dairy Products Used for Preventing and Treating Obesity or Diabetes Mellitus and Manufacturing Method thereof | |
| CN115944665A (en) | Probiotic agent for improving intestinal flora balance and preparation method and application thereof | |
| CN115120646A (en) | Probiotic composition for balancing intestinal flora and preparation method and application thereof | |
| CN112970990A (en) | Probiotic solid beverage with weight-losing and lipid-lowering effects and preparation process thereof | |
| CN111134263A (en) | Probiotic solid beverage with diarrhea relieving effect and preparation method thereof | |
| CN110710627A (en) | Functional probiotic solid beverage and preparation method thereof | |
| CN113208077A (en) | Preparation method of probiotic medlar vinegar jelly | |
| CN108938789A (en) | A kind of more bacterium combination formulations of the adjusting intestinal microecology containing xylo-oligosaccharide | |
| CN117204573B (en) | Composite prebiotic concentrate with effect of improving intestinal health and preparation method and application thereof | |
| CN111248384A (en) | Composite probiotic enzyme beverage and preparation method thereof | |
| CN110801003A (en) | Calcium fruit enzyme powder and preparation method thereof | |
| CN109090533A (en) | A kind of preparation method of pulp-water synbiotic | |
| CN115349585A (en) | Composite prebiotic composition for regulating human intestinal function, preparation process and application thereof | |
| JP2004269407A (en) | Constipation ameliorant and food and beverage containing the same | |
| CN112971156A (en) | Grape leaf dietary fiber extract and preparation method thereof | |
| CN104957617A (en) | Stachys probiotic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |